Ingelheim, Germany – 23 November, 2011 – Boehringer Ingelheim's breakthrough novel oral anticoagulant Pradaxa® (dabigatran etexilate) was awarded the prestigious Prix Galien in Canada. At a Gala Ceremony during the Tenth Annual Canadian Health Research Awards Ceremony in Ottawa, Pradaxa® (Pradax® in Canada) was recognised as the most innovative Canadian product in 2011. Pradaxa® has now received this award for the second time, after winning the German Prix Galien in 2010, in the Primary Care category. The Prix Galien is awarded for new drugs representing a significant advance in pharmaceutical research.
Pradaxa® awarded Prix Galien for most innovative product in Canada
- For NON-US, Non-Canada and NON-UK Healthcare Media Only
Nov 28th, 2011
